Meaterm LogoMeaterm LogoMeaterm
Stock research

JOHNSON & JOHNSON (JNJ) stock

Healthcare·Pharmaceutical Preparations·Market cap $630.0B
Auto-Brief · synthesised from 5 layers
JNJ · us_stock
BULLISH
Top reasons
  1. 1Revenue growth 8.1% YoY, net margin 21.5%.
  2. 2earnings: JNJ Q3 2026 earnings reported (scheduled 2026-10-13)
Generated 2026-10-13 21:15 UTC5 layers
Meaterm briefs are analytical research. Not investment advice. Not a recommendation to buy, sell, or hold any asset.

Factor grades

As of 2026-10-12
Meaterm Score
B-
55th percentile
Valuation
D
30th percentile
Growth
C
51st percentile
Profitability
B
75th percentile
Momentum
B-
66th percentile

Percentile grades within the stock’s sector, computed nightly from SEC filings. Statistical ranking, not investment advice.

Fair value estimate

Fair value estimate
—

No estimate: the comparable companies’ median multiples are outside a plausible range, so they cannot price this company.

Research JNJ with the full toolkit
Charts, screeners, factor rankings, filings and positioning data in one browser-based terminal. Free tier, no card required.
Open JNJ in the Meaterm terminal →
MacroNEUTRALNo feed
0 items
  • No macro events in the recency window.
No macro events in the recency window.
CatalystsBULLISHLive
1 item
  • earnings: JNJ Q3 2026 earnings reported (scheduled 2026-10-13)
  1. earningsScheduled 2026-10-13
    JNJ Q3 2026 earnings reported
    Reported EPS 2.59 vs. estimate 2.59.
    BULLISH
FundamentalsBULLISHLive
1 item
  • Revenue growth 8.1% YoY, net margin 21.5%.
  • Forward P/E —, FCF $17.8B.
Revenue growth (YoY)
8.1%
>10% strong
Net margin
21.5%
>15% healthy
Debt / Equity
0.58
<1 conservative
Interest coverage
—
Beta
—
Forward P/E
—
Free cash flow
$17.8B
TTM
Earnings beat rate
—
As of 2026-06-28 · Issuer filings + market data
PositioningNEUTRALNo feed
0 items
  • Peers: 151 of 237 recently-briefed us stock names lean bullish.
As of 2026-10-13 · Meaterm
NewsNEUTRALNo feed
0 items
  • No news in the recency window.
  • Signal steady (bullish) vs the last brief.
  • 5 ongoing stories tracked in the knowledge base.
No news in the recency window.

Key fundamentals

Revenue (TTM)
$97.9B
Net income (TTM)
$21.0B
Diluted EPS (TTM)
$8.61
Gross margin
67.9%
Operating margin
—
Net margin
21.5%

Trailing-twelve-month figures computed by Meaterm from SEC filings, refreshed nightly.

Related Pharmaceutical Preparations stocks

LLYELI LILLY & CoONCBeOne Medicines Ltd.ABBVAbbVie Inc.MRKMerck & Co., Inc.ABTABBOTT LABORATORIES

Frequently asked questions

What are the JNJ factor grades?

Meaterm scores JOHNSON & JOHNSON (JNJ) on four factors — valuation, growth, profitability and momentum — plus an overall Meaterm Score. Each grade is a percentile ranking against the stock's sector, computed nightly from SEC-filed financial data. Grades are statistical rankings, not investment advice or a recommendation to trade.

How is the fair value estimate for JNJ calculated?

The estimate is the median of several peer-multiple implied values — peer P/E, EV/EBITDA, P/S and P/B applied to the company's own fundamentals — plus a sell-side consensus target when one is available. Peers come from the same industry, matched by size. When the company’s own size is not on record, or the comparable companies are too few, more than ten times larger or smaller, or disagree too much with each other or with the market price, no estimate is published and the page says why. It is a statistical reference point, not a price target and not investment advice.

Where does the data on this page come from?

Fundamentals and factor grades are computed by Meaterm from SEC filings and refreshed nightly. Positioning context comes from public CFTC and FINRA releases, and macro series from FRED. Every signal, grade and estimate shown is Meaterm’s own computation.

Is JNJ a good stock to invest in?

Meaterm does not answer that question. This page shows how JOHNSON & JOHNSON (JNJ) ranks statistically against sector peers on valuation, growth, profitability and momentum and, where its peer group supports one, where its price sits relative to a peer-multiple estimate. Use it as research context alongside your own analysis — nothing on this page is investment advice.

How often is this page updated?

Factor grades, fundamentals and the company profile refresh nightly after each trading day. The brief layers — macro, catalysts, positioning and news — are composed when the page loads, and the fair value estimate is recomputed with recent quotes during the day.